EuroPCR, Paris, Late Breaking Trials, Hot Line Session, Friday, 20th May 2011, Room 342AB Chairpersons: C.Di Mario, M.Sabaté, D.O Williams

During the late breaking registries and trial updates sessions held during the EuroPCR 2011 congress, the results of the large scale, multicenter, prospective registry "CATS-AMI" were presented by Dr Michaël Angioi (Institut Lorrain du Coeur et des Vaisseaux, Nancy University Hospital, France).

Between May 2008 and August 2010, 2137 patients have been enrolled in 38 french sites. The inclusion criteria were STEMI patients with culprit lesion treated by Titan2 bio-active stent: Primary PCI, rescue PCI following failed thrombolysis and PCI within 24 hours following successful thrombolysis as well as NSTEMI with culprit lesion treated within 72 hours.

Titan2 Bio Active Stent (BAS), Hexacath France, coated with a non-drug biological active compound called Titanium-Nitride-Oxide has shown low MACE rates of 3.6% at 1 month and 9.8% at 12 months in a particularly challenging and pro-thrombotic population. This large scale registry confirmed the previously reported Bio Active Stent results from both randomized and non- randomized studies and reinforces the existing body of evidence (17 existing scientific publications) supporting the efficacy and the safety profile of the Titan2 Bio Active Stent (BAS).

Source: Hexacath